RELL2 Activators

The chemical class termed RELL2 activators encompasses compounds that influence RELL2 by modulating immune signaling pathways, TNFR-associated pathways, or general cellular signaling mechanisms. These activators do not directly target RELL2, but they can affect its activity through alterations in the immune signaling environment or by influencing pathways that are associated with the functions of RELL2. Thalidomide, Lenalidomide, and Pomalidomide are immunomodulatory drugs that affect TNF-α signaling, potentially impacting pathways associated with RELL2. Infliximab, Etanercept, and Adalimumab are TNF-α inhibitors and could indirectly influence RELL2 activity by modulating the TNF signaling pathway. These compounds are known for their roles in regulating inflammatory responses and immune signaling, processes in which RELL2 could be involved.

Tofacitinib and Baricitinib are JAK inhibitors, which affect cytokine signaling pathways that could be relevant to the signaling mechanisms of RELL2. Anakinra, an IL-1 receptor antagonist, impacts interleukin signaling, which might also be relevant to RELL2 activity. Methotrexate, Cyclosporine, and Azathioprine are immunosuppressants that modulate various aspects of the immune system and could indirectly affect RELL2 through their broad effects on immune signaling. The overall influence of these activators is characterized by a modulation of immune response, cytokine signaling, and inflammation, leading to alterations in RELL2 activity within the cell.